NCT07140978

Brief Summary

This is a 16-week, two-arm, hybrid, randomized controlled clinical trial designed to evaluate the effect of the Green Chef Calorie Smart \& Brain Health meal plans on health biomarkers and perceived well-being. The study aims to measure improvements in blood lipids, body composition, weight, and blood pressure, as well as subjective health indicators through surveys.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Nov 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 19, 2024

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2025

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

August 21, 2025

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 26, 2025

Completed
Last Updated

August 26, 2025

Status Verified

August 1, 2025

Enrollment Period

7 months

First QC Date

August 21, 2025

Last Update Submit

August 21, 2025

Conditions

Keywords

Healthy meal planWeight management

Outcome Measures

Primary Outcomes (3)

  • Change in Blood Lipid Biomarkers (LDL, HDL, Triglycerides)

    Blood lipid levels (LDL, HDL, triglycerides) will be measured at baseline and week 16 via fasting blood draws to evaluate the effect of the Green Chef meal plan on cardiovascular health.

    Baseline to Week 16

  • Change in Weight and Body Composition

    Body weight and composition will be measured using a Withings smart scale at baseline, week 8, and week 16 to assess changes related to the dietary intervention.

    Baseline, Week 8, Week 16

  • Change in Blood Pressure

    Systolic and diastolic blood pressure will be measured using a Withings smart blood pressure cuff at baseline, week 8, and week 16 to assess impact of the meal plan on cardiovascular function.

    Baseline, Week 8, Week 16

Secondary Outcomes (1)

  • Change in Self-Reported Health Perceptions

    Baseline, Week 4, Week 8, Week 12, Week 16

Study Arms (2)

Intervention Group

EXPERIMENTAL

Participants in the intervention group will receive Green Chef meals for lunch and dinner, along with guidelines for preparing healthy breakfasts. Participants will follow this diet for 16 weeks.

Dietary Supplement: Green Chef Meal Delivery Program

Control Group

NO INTERVENTION

Participants in the control group will continue their usual eating habits with no dietary changes for 16 weeks.

Interventions

Participants will receive Green Chef meals for lunch and dinner, delivered weekly for 16 weeks. Meals include organic produce, responsibly sourced protein, and nutritionist-approved recipes. Participants will also receive guidelines for preparing healthy breakfasts and will use smart devices to record biomarker data.

Intervention Group

Eligibility Criteria

Age25 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Males and females aged 25 years or older.
  • Participants who struggle with healthy weight management and have a desire to lose weight.
  • Participants who eat takeout or at restaurants at least four times per week.
  • Participants not currently using a meal kit.
  • Participants who are willing to cook meals twice daily for the 16-week study period.
  • Participants who are willing to cook and consume meals as instructed, fill out regular questionnaires, take regular weight and blood pressure measurements, and attend blood tests at Quest for Baseline and Endline assessments for the 16-week study period.
  • Participants must not have introduced any new prescription medications, supplements, or herbal remedies targeting weight management within the past three months.
  • Participants must be willing to discontinue any prescription medications, supplements, or herbal remedies that target weight management for the duration of the trial.
  • Participants must agree to not introduce any new prescription medications, vitamins, minerals, nutraceuticals, or herbal supplements for the duration of the trial.
  • Participants must consider themselves in good general health and not have any chronic health conditions that could impact their participation in the study.
  • Participants must reside in the United States.

You may not qualify if:

  • Individuals who have undergone surgeries or invasive treatments in the last six months or have any planned for the duration of the trial.
  • Individuals who have undergone weight loss surgery.
  • Individuals who have experienced dramatic weight changes (gain or loss) within the past three months.
  • Individuals who consider themselves to be chronic dieters or "always on a diet" (e.g., those who have been dieting or restricting calories for a prolonged period of time or who tend to jump from one diet to the next regularly).
  • Individuals with a known history of severe digestive disorders, including but not limited to acid reflux, Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), ulcerative colitis (UC), Crohn's disease, or gastrointestinal tract surgeries.
  • Individuals with a known history of any chronic illness such as hypertension, diabetes, or cancer.
  • Individuals with any known allergies or hypersensitivities to foods.
  • Individuals with a history of disordered eating behaviors or an eating disorder.
  • Individuals who regularly take laxatives, or antacids.
  • Individuals who regularly take anticoagulants (also referred to as blood thinners).
  • Individuals with chronic health conditions, including oncological or psychiatric disorders, that could impact participation.
  • Individuals with known serious allergic reactions requiring the use of an Epi-Pen.
  • Individuals who are currently pregnant, trying to conceive, or breastfeeding.
  • Individuals currently participating or planning to participate in another research study within the next 16 weeks.
  • Individuals with a history of substance abuse.
  • +2 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Citruslabs

Las Vegas, Nevada, 89118, United States

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 21, 2025

First Posted

August 26, 2025

Study Start

November 19, 2024

Primary Completion

June 30, 2025

Study Completion

June 30, 2025

Last Updated

August 26, 2025

Record last verified: 2025-08

Locations